Alzheimer's Unmet Need
The need for new Alzheimer's therapies is great as no currently approved drugs alter disease progression, and multiple drug candidates have failed clinical development.
Challenges in Alzheimer's drug development have been attributed to drug candidate mechanisms of action, and/or routes of administration.
Immune and/or antibody-based approaches, and those targeting pathways not specific to Alzheimer's disease have presented challenges.
Peripheral injection and/or administration by mouth have also presented challenges, given the need for an Alzheimer's drug to bypass the blood-brain barrier to reach therapeutic levels in the brain.
See how GYRUS's approach to treating Alzheimer's aims to address these challenges.
